This HTML5 document contains 54 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n7http://linked.opendata.cz/resource/mesh/concept/
n11http://linked.opendata.cz/resource/drugbank/drug/DB04894/identifier/chemspider/
n19http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n18http://linked.opendata.cz/resource/drugbank/drug/DB04894/identifier/pharmgkb/
n14http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n6http://linked.opendata.cz/ontology/mesh/
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n17http://linked.opendata.cz/resource/drugbank/drug/DB04894/identifier/pubchem-compound/
n4http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n15http://linked.opendata.cz/resource/drugbank/drug/DB04894/identifier/pubchem-substance/
n16http://linked.opendata.cz/resource/drugbank/drug/DB04894/identifier/kegg-drug/
n9http://linked.opendata.cz/resource/atc/
n12http://linked.opendata.cz/resource/drugbank/drug/DB04894/identifier/drugbank/
n8http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB04894
rdf:type
n3:Drug
n3:description
Vapreotide is a synthetic octapeptide somatostatin analog. It was being studied for the treatment of cancer.
n3:generalReferences
# Sarr MG: The potent somatostatin analogue vapreotide does not decrease pancreas-specific complications after elective pancreatectomy: a prospective, multicenter, double-blinded, randomized, placebo-controlled trial. J Am Coll Surg. 2003 Apr;196(4):556-64; discussion 564-5; author reply 565. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/12691930 # Vapreotide: BMY 41606, RC 160, Sanvar. Drugs R D. 2003;4(5):326-30. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/12952505 # Norman P: Vapreotide (Debipharm). IDrugs. 2000 Nov;3(11):1358-72. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16047258 # Betoin F, Ardid D, Herbet A, Aumaitre O, Kemeny JL, Duchene-Marullaz P, Lavarenne J, Eschalier A: Evidence for a central long-lasting antinociceptive effect of vapreotide, an analog of somatostatin, involving an opioidergic mechanism. J Pharmacol Exp Ther. 1994 Apr;269(1):7-14. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/7909563 # Girard PM, Goldschmidt E, Vittecoq D, Massip P, Gastiaburu J, Meyohas MC, Coulaud JP, Schally AV: Vapreotide, a somatostatin analogue, in cryptosporidiosis and other AIDS-related diarrhoeal diseases. AIDS. 1992 Jul;6(7):715-8. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/1354449 # Stiefel F, Morant R: Vapreotide, a new somatostatin analogue in the palliative management of obstructive ileus in advanced cancer. Support Care Cancer. 1993 Jan;1(1):57-8. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/7511473 # Betoin F, Eschalier A, Duchene-Marullaz P, Lavarenne J: Seven-day antinociceptive effect of a sustained release vapreotide formulation. Neuroreport. 1994 Jan 31;5(5):642-4. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/7912964
n3:group
approved investigational
n3:halfLife
30 minutes
n3:indication
For the treatment of esophageal variceal bleeding in patients with cirrhotic liver disease and has also shown efficacy in the treatment of patients with AIDS-related diarrhea.
owl:sameAs
n14:DB04894 n19:DB04894
dcterms:title
Vapreotide
adms:identifier
n11:64425 n12:DB04894 n15:46506923 n16:D06281 n17:23725064 n18:PA164743146
n3:mechanismOfAction
The exact mechanism of action is unknown, although one study has provided in vitro and in vivo evidence for a tachykinin NK1 receptor antagonist effect in the analgesic effects of vapreotide (PMID: 7556407).
n3:routeOfElimination
Vapreotide is 76% eliminated in bile. The remainder is renally eliminated.
n3:synonym
Vapreotida Vapreotidum
n3:toxicity
Safety data are limited, however, headache, fatigue, diarrhea, nausea, vomiting, and abdominal pain have been reported commonly with the use of vapreotide.
n3:salt
n3:synthesisReference
Venkata Raghavendra Palle, Maheedhara Reddy Challa, "PROCESS FOR PREPARING VAPREOTIDE." U.S. Patent US20070111930, issued May 17, 2007.
n6:hasConcept
n7:M0146450
n3:IUPAC-Name
n4:271B5DC9-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B5DCF-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B5DCE-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B5DCB-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B5DCC-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B5DCD-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B5DC7-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B5DC5-363D-11E5-9242-09173F13E4C5 n4:271B5DC8-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B5DC6-363D-11E5-9242-09173F13E4C5
n8:hasATCCode
n9:H01CB04
n3:H-Bond-Acceptor-Count
n4:271B5DD5-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B5DD6-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B5DD0-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B5DD1-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B5DD3-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B5DD2-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B5DD4-363D-11E5-9242-09173F13E4C5
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
103222-11-3
n3:category
n3:Bioavailability
n4:271B5DDB-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B5DDD-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B5DDE-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B5DDA-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B5DD9-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B5DDC-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B5DCA-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B5DD7-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B5DD8-363D-11E5-9242-09173F13E4C5